Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03786783
Title Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

ganglioneuroblastoma

neuroblastoma

Therapies

Isotretinoin

Cyclophosphamide + Thiotepa

Cisplatin + Dinutuximab + Etoposide + Sargramostim

Cyclophosphamide + Dinutuximab + Doxorubicin + Sargramostim + Vincristine Sulfate

Dexrazoxane

Cyclophosphamide + Topotecan

Dinutuximab + Isotretinoin + Sargramostim

Carboplatin + Etoposide + Melphalan

Age Groups: child | adult
Covered Countries USA

Facility Status City State Zip Country Details
Children's Hospital Los Angeles Los Angeles California 90027 United States Details
Children's National Medical Center Washington District of Columbia 20010 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032 United States Details
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15224 United States Details
Saint Jude Children's Research Hospital Memphis Tennessee 38105 United States Details
Primary Children's Hospital Salt Lake City Utah 84113 United States Details
The Children's Hospital at Westmead Westmead New South Wales 2145 Australia Details
Royal Children's Hospital Parkville Victoria 3052 Australia Details
Starship Children's Hospital Grafton Auckland 1145 New Zealand Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field